Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Whole-Body Irradiation 27Specimen Handling 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lidocaine, Prilocaine Drug Combination × Dermatologic × Clear all
NCT06223659 2026-03-10

EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
100 enrolled
Dermatologic

Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡